| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Access divergence to new cancer medicines in the United Kingdom
|
Lythgoe, Mark P.
|
|
|
207 |
C |
p.
|
artikel
|
| 2 |
A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: The importance of trial design
|
Verschoor, Noortje
|
|
|
207 |
C |
p.
|
artikel
|
| 3 |
A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease
|
Lopez-Olivo, Maria A.
|
|
|
207 |
C |
p.
|
artikel
|
| 4 |
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
|
Haslam, Alyson
|
|
|
207 |
C |
p.
|
artikel
|
| 5 |
Corrigendum to “Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021″ Volume 205, July 2024, 114104
|
Swartjes, Hidde
|
|
|
207 |
C |
p.
|
artikel
|
| 6 |
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
|
Verheijden, Rik J.
|
|
|
207 |
C |
p.
|
artikel
|
| 7 |
EBCC-14 manifesto: Addressing disparities in access to innovation for patients with metastatic breast cancer across Europe
|
Ignatiadis, Michail
|
|
|
207 |
C |
p.
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
207 |
C |
p.
|
artikel
|
| 9 |
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
|
Nicolò, Eleonora
|
|
|
207 |
C |
p.
|
artikel
|
| 10 |
Exploring the biology of ctDNA release in colorectal cancer
|
Andersen, Laura
|
|
|
207 |
C |
p.
|
artikel
|
| 11 |
Impact of cyclin dependent kinase 4/6 inhibitors on breast cancer brain metastasis outcomes
|
Chew, Sonya M.
|
|
|
207 |
C |
p.
|
artikel
|
| 12 |
Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations
|
Kron, Anna
|
|
|
207 |
C |
p.
|
artikel
|
| 13 |
Letter re: ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
|
Zhu, Ning
|
|
|
207 |
C |
p.
|
artikel
|
| 14 |
Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
|
Hong, Hujian
|
|
|
207 |
C |
p.
|
artikel
|
| 15 |
Letter re: Ki-67 index after neoadjuvant endocrine therapy as a prognostic biomarker in patients with ER-positive/HER2-negative early breast cancer: A systematic review and meta-analysis
|
Han, Wei
|
|
|
207 |
C |
p.
|
artikel
|
| 16 |
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
|
Pressiani, Tiziana
|
|
|
207 |
C |
p.
|
artikel
|
| 17 |
Open-label, phase II study of talimogene laherparepvec plus pembrolizumab for the treatment of advanced melanoma that progressed on prior anti–PD-1 therapy: MASTERKEY-115,
|
Robert, Caroline
|
|
|
207 |
C |
p.
|
artikel
|
| 18 |
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer
|
Chen, Chengcong
|
|
|
207 |
C |
p.
|
artikel
|
| 19 |
Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer
|
Pearson, Andrew DJ
|
|
|
207 |
C |
p.
|
artikel
|
| 20 |
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
|
Cohen, Romain
|
|
|
207 |
C |
p.
|
artikel
|
| 21 |
Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma
|
Kubota, Shoko
|
|
|
207 |
C |
p.
|
artikel
|
| 22 |
Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation
|
Michiel Zeeuw, J.
|
|
|
207 |
C |
p.
|
artikel
|
| 23 |
Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor
|
Toublanc, Anne-Claire
|
|
|
207 |
C |
p.
|
artikel
|
| 24 |
Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial
|
Seefat, M.R.
|
|
|
207 |
C |
p.
|
artikel
|
| 25 |
Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma
|
Luke, Jason J.
|
|
|
207 |
C |
p.
|
artikel
|
| 26 |
The challenge of running trials in advanced angiosarcoma: A systematic review of the literature from EORTC/STBSG to guide the development of angiosarcoma-specific trials
|
Dufresne, Armelle
|
|
|
207 |
C |
p.
|
artikel
|
| 27 |
The development of an archive of patient-reported outcome measures (PROMs) in oncology: The Italian PRO4All project
|
Malandrini, Francesco
|
|
|
207 |
C |
p.
|
artikel
|
| 28 |
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
|
Krebs, Markus
|
|
|
207 |
C |
p.
|
artikel
|
| 29 |
Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module
|
Egeler, M.D.
|
|
|
207 |
C |
p.
|
artikel
|
Tijdschrift beschrijving